AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
GENFIT Signs Research Partnership with EVerZom to Advance Exosome-Based Regenerative Medicine Technology in ACLF.
ByAinvest
Monday, Nov 10, 2025 1:47 am ET1min read
GENFIT has partnered with EVerZom to advance a regenerative medicine technology based on exosomes for the treatment of Acute-on-Chronic Liver Failure (ACLF). The experimental drug candidate EViv, developed by EVerZom using its proprietary exosome platform, represents a novel approach in regenerative therapies. GENFIT will lead the preclinical evaluation of EViv, while EVerZom will provide its unique expertise in exosomes and bioproduction platform. In case of positive in vivo proof-of-concept results, GENFIT has an exclusive option to license EViv for further clinical development.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Incβs editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
ο»Ώ
No comments yet